Skip to main content
Erschienen in: Annals of Surgical Oncology 13/2022

17.08.2022 | Pancreatic Tumors

Prognostic Factors After Pancreatectomy for Pancreatic Cancer Initially Metastatic to the Liver

verfasst von: Isabella Frigerio, MD, PhD, Giuseppe Malleo, MD, PhD, Matteo de Pastena, MD, PhD, Giacomo Deiro, MD, Niccolò Surci, MD, Filippo Scopelliti, MD, Alessandro Esposito, MD, Paolo Regi, MD, Alessandro Giardino, MD, PhD, Valentina Allegrini, MD, Claudio Bassi, MD, Roberto Girelli, MD, Roberto Salvia, MD, PhD, Giovanni Butturini, MD, PhD

Erschienen in: Annals of Surgical Oncology | Ausgabe 13/2022

Einloggen, um Zugang zu erhalten

Abstract

Background

Resection of initially oligometastatic pancreatic ductal adenocarcinoma (PDAC) following response to first-line chemotherapy is controversial. We herein updated a previous case series to investigate the oncologic outcomes and preoperative factors that could drive the decision-making process.

Methods

This retrospective analysis was limited to patients with liver-only synchronous metastases who experienced complete regression of the metastatic component and underwent pancreatectomy between October 2008 and July 2020 at two high-volume institutions. Clinical-pathologic variables were captured, and inflammation-based prognostic scores were calculated. Recurrence and survival analyses were performed using standard statistical methods.

Results

Overall, 52 patients were included. FOLFIRINOX was the most employed chemotherapy regimen (63.5%). Post-treatment tumor size, serum carbohydrate antigen (CA) 19-9 and carcinoembryonic antigen (CEA) were significantly decreased relative to baseline evaluation. The median time from diagnosis to pancreatectomy was 10.2 months, while the median time from chemotherapy completion to pancreatectomy was 2 months. Major postoperative complications occurred in 26.9% of patients, while postoperative mortality was nil. The median disease-free survival (DFS) and overall survival (OS) from pancreatectomy were 16.5 and 23.0 months, respectively, and the median OS from diagnosis was 37.2 months. At multivariable analysis, vascular resection, operative time, prognostic nutrition index (PNI) and neutrophil-to-lymphocyte ratio (NLR) were associated with OS. Operative time, platelet × neutrophil/lymphocyte count (SII), and PNI were associated with DFS.

Conclusions

We confirm promising outcomes of selected patients who underwent pancreatectomy following downstaging of liver metastases. The absence of vascular involvement of the primary tumor, good nutritional status, and low inflammatory index scores could be useful to select candidates for resection.
Literatur
1.
Zurück zum Zitat Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 202. CA Cancer J Clin. 2022;72:7–33.CrossRefPubMed Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 202. CA Cancer J Clin. 2022;72:7–33.CrossRefPubMed
2.
3.
Zurück zum Zitat Shrikhande SV, Kleeff J, Reiser C, et al. Pancreatic resection for M1 pancreatic ductal adenocarcinoma. Ann Surg Oncol. 2006;14:118–27.CrossRefPubMed Shrikhande SV, Kleeff J, Reiser C, et al. Pancreatic resection for M1 pancreatic ductal adenocarcinoma. Ann Surg Oncol. 2006;14:118–27.CrossRefPubMed
4.
Zurück zum Zitat Antoniou E, Margonis GA, Sasaki K, et al. Is resection of pancreatic adenocarcinoma with synchronous hepatic metastasis justified? A review of current literature. ANZ J Surg. 2016;86:973–7.CrossRefPubMed Antoniou E, Margonis GA, Sasaki K, et al. Is resection of pancreatic adenocarcinoma with synchronous hepatic metastasis justified? A review of current literature. ANZ J Surg. 2016;86:973–7.CrossRefPubMed
5.
Zurück zum Zitat Buc E, Orry D, Antomarchi O, Gagnière J, Da Ines D, Pezet D. Resection of pancreatic ductal adenocarcinoma with synchronous distant metastasis: is it worthwhile? World J Surg Oncol. 2014;12:347.CrossRefPubMedPubMedCentral Buc E, Orry D, Antomarchi O, Gagnière J, Da Ines D, Pezet D. Resection of pancreatic ductal adenocarcinoma with synchronous distant metastasis: is it worthwhile? World J Surg Oncol. 2014;12:347.CrossRefPubMedPubMedCentral
6.
Zurück zum Zitat Tachezy M, Gebauer F, Janot M, et al. Synchronous resections of hepatic oligometastatic pancreatic cancer: disputing a principle in a time of safe pancreatic operations in a retrospective multicenter analysis. Surgery. 2016;160:136–44.CrossRefPubMed Tachezy M, Gebauer F, Janot M, et al. Synchronous resections of hepatic oligometastatic pancreatic cancer: disputing a principle in a time of safe pancreatic operations in a retrospective multicenter analysis. Surgery. 2016;160:136–44.CrossRefPubMed
7.
Zurück zum Zitat Hackert T, Niesen W, Hinz U, et al. Radical surgery of oligometastatic pancreatic cancer. Eur J Surg Oncol. 2017;43:358–63.CrossRefPubMed Hackert T, Niesen W, Hinz U, et al. Radical surgery of oligometastatic pancreatic cancer. Eur J Surg Oncol. 2017;43:358–63.CrossRefPubMed
8.
Zurück zum Zitat Tao L, Yuan C, Ma Z, Jiang B, Xiu D. Surgical resection of a primary tumor improves survival of metastatic pancreatic cancer: a population-based study. Cancer Manag Res. 2017;9:471–9.CrossRefPubMedPubMedCentral Tao L, Yuan C, Ma Z, Jiang B, Xiu D. Surgical resection of a primary tumor improves survival of metastatic pancreatic cancer: a population-based study. Cancer Manag Res. 2017;9:471–9.CrossRefPubMedPubMedCentral
9.
Zurück zum Zitat Oweira H, Petrausch U, Helbling D, et al. Prognostic value of site-specific metastases in pancreatic adenocarcinoma: a surveillance epidemiology and end results database analysis. World J Gastroenterol. 2017;23:1872–80.CrossRefPubMedPubMedCentral Oweira H, Petrausch U, Helbling D, et al. Prognostic value of site-specific metastases in pancreatic adenocarcinoma: a surveillance epidemiology and end results database analysis. World J Gastroenterol. 2017;23:1872–80.CrossRefPubMedPubMedCentral
10.
11.
Zurück zum Zitat Conroy T, Desseigne F, Ychou M, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011;364:1817–25.CrossRefPubMed Conroy T, Desseigne F, Ychou M, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011;364:1817–25.CrossRefPubMed
12.
Zurück zum Zitat Von Hoff DD, Ervin T, Arena FP, et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med. 2013;369:1691–703.CrossRef Von Hoff DD, Ervin T, Arena FP, et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med. 2013;369:1691–703.CrossRef
13.
Zurück zum Zitat Kandel P, Wallace MB, Stauffer J, et al. Survival of patients with oligometastatic pancreatic ductal adenocarcinoma treated with combined modality treatment including surgical resection: a pilot study. J Pancreat Cancer. 2018;4:88–94.CrossRefPubMedPubMedCentral Kandel P, Wallace MB, Stauffer J, et al. Survival of patients with oligometastatic pancreatic ductal adenocarcinoma treated with combined modality treatment including surgical resection: a pilot study. J Pancreat Cancer. 2018;4:88–94.CrossRefPubMedPubMedCentral
14.
Zurück zum Zitat Crippa S, Bittoni A, Sebastiani E, et al. Is there a role for surgical resection in patients with pancreatic cancer with liver metastases responding to chemotherapy? Eur J Surg Oncol. 2016;42:1533–9.CrossRefPubMed Crippa S, Bittoni A, Sebastiani E, et al. Is there a role for surgical resection in patients with pancreatic cancer with liver metastases responding to chemotherapy? Eur J Surg Oncol. 2016;42:1533–9.CrossRefPubMed
15.
Zurück zum Zitat Byun Y, Han Y, Kang JS, et al. Role of surgical resection in the era of FOLFIRINOX for advanced pancreatic cancer. J Hepato-Biliary-Pancreat Sci. 2019;26:416–25.CrossRef Byun Y, Han Y, Kang JS, et al. Role of surgical resection in the era of FOLFIRINOX for advanced pancreatic cancer. J Hepato-Biliary-Pancreat Sci. 2019;26:416–25.CrossRef
16.
Zurück zum Zitat Tanaka M, Heckler M, Mihaljevic AL, et al. CT response of primary tumor and CA19-9 predict resectability of metastasized pancreatic cancer after FOLFIRINOX. Eur J Surg Oncol. 2019;45:1453–9.CrossRefPubMed Tanaka M, Heckler M, Mihaljevic AL, et al. CT response of primary tumor and CA19-9 predict resectability of metastasized pancreatic cancer after FOLFIRINOX. Eur J Surg Oncol. 2019;45:1453–9.CrossRefPubMed
17.
Zurück zum Zitat Wright GP, Poruk KE, Zenati MS, et al. Primary tumor resection following favorable response to systemic chemotherapy in stage IV pancreatic adenocarcinoma with synchronous metastases: a bi-institutional analysis. J Gastrointest Surg. 2016;20:1830–5.CrossRefPubMed Wright GP, Poruk KE, Zenati MS, et al. Primary tumor resection following favorable response to systemic chemotherapy in stage IV pancreatic adenocarcinoma with synchronous metastases: a bi-institutional analysis. J Gastrointest Surg. 2016;20:1830–5.CrossRefPubMed
18.
Zurück zum Zitat Nie D, Lai G, An G, et al. Individualized prediction of survival benefits of pancreatectomy plus chemotherapy in patients with simultaneous metastatic pancreatic cancer. Front Oncol. 2021;11:719253.CrossRefPubMedPubMedCentral Nie D, Lai G, An G, et al. Individualized prediction of survival benefits of pancreatectomy plus chemotherapy in patients with simultaneous metastatic pancreatic cancer. Front Oncol. 2021;11:719253.CrossRefPubMedPubMedCentral
19.
Zurück zum Zitat Frigerio I, Regi P, Giardino A, et al. Downstaging in stage IV pancreatic cancer: a new population eligible for surgery? Ann Surg Oncol. 2017;24:2397–403.CrossRefPubMed Frigerio I, Regi P, Giardino A, et al. Downstaging in stage IV pancreatic cancer: a new population eligible for surgery? Ann Surg Oncol. 2017;24:2397–403.CrossRefPubMed
20.
Zurück zum Zitat Crippa S, Cirocchi R, Weiss MJ, et al. A systematic review of surgical resection of liver-only synchronous metastases from pancreatic cancer in the era of multiagent chemotherapy. Updates Surg. 2020;72:39–45.CrossRefPubMed Crippa S, Cirocchi R, Weiss MJ, et al. A systematic review of surgical resection of liver-only synchronous metastases from pancreatic cancer in the era of multiagent chemotherapy. Updates Surg. 2020;72:39–45.CrossRefPubMed
21.
Zurück zum Zitat De Simoni O, Scarpa M, Tonello M, et al. Oligometastatic pancreatic cancer to the liver in the era of neoadjuvant chemotherapy: Which role for conversion surgery? A systematic review and meta-analysis. Cancers. 2020;12:3402.CrossRefPubMedCentral De Simoni O, Scarpa M, Tonello M, et al. Oligometastatic pancreatic cancer to the liver in the era of neoadjuvant chemotherapy: Which role for conversion surgery? A systematic review and meta-analysis. Cancers. 2020;12:3402.CrossRefPubMedCentral
22.
Zurück zum Zitat Bassi C, Marchegiani G, Dervenis C, et al. The 2016 update of the International Study Group (ISGPS) definition and grading of postoperative pancreatic fistula: 11 Years After. Surgery. 2017;161:584–91.CrossRefPubMed Bassi C, Marchegiani G, Dervenis C, et al. The 2016 update of the International Study Group (ISGPS) definition and grading of postoperative pancreatic fistula: 11 Years After. Surgery. 2017;161:584–91.CrossRefPubMed
23.
Zurück zum Zitat Wente MN, Veit JA, Bassi C, et al. Postpancreatectomy hemorrhage (PPH)–an international study group of pancreatic surgery (ISGPS) definition. Surgery. 2007;142:20–5.CrossRefPubMed Wente MN, Veit JA, Bassi C, et al. Postpancreatectomy hemorrhage (PPH)–an international study group of pancreatic surgery (ISGPS) definition. Surgery. 2007;142:20–5.CrossRefPubMed
24.
Zurück zum Zitat Wente MN, Bassi C, Dervenis C, et al. Delayed gastric emptying (DGE) after pancreatic surgery: a suggested definition by the International Study Group of Pancreatic Surgery (ISGPS). Surgery. 2007;142:761–8.CrossRefPubMed Wente MN, Bassi C, Dervenis C, et al. Delayed gastric emptying (DGE) after pancreatic surgery: a suggested definition by the International Study Group of Pancreatic Surgery (ISGPS). Surgery. 2007;142:761–8.CrossRefPubMed
25.
Zurück zum Zitat Dindo D, Demartines N, Clavien PA. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg. 2004;240:205–13.CrossRefPubMedPubMedCentral Dindo D, Demartines N, Clavien PA. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg. 2004;240:205–13.CrossRefPubMedPubMedCentral
26.
Zurück zum Zitat Jabłońska B, Pawlicki K, Mrowiec S. Associations between nutritional and immune status and clinicopathologic factors in patients with pancreatic cancer: a comprehensive analysis. Cancers. 2021;13:5041.CrossRefPubMedPubMedCentral Jabłońska B, Pawlicki K, Mrowiec S. Associations between nutritional and immune status and clinicopathologic factors in patients with pancreatic cancer: a comprehensive analysis. Cancers. 2021;13:5041.CrossRefPubMedPubMedCentral
27.
Zurück zum Zitat Edge SB, Byrd DR, Compton CC, et al editors. AJCC Cancer Staging Manual. 7th edn. New York: Springer; 2010. Edge SB, Byrd DR, Compton CC, et al editors. AJCC Cancer Staging Manual. 7th edn. New York: Springer; 2010.
28.
Zurück zum Zitat Pausch TM, Liu X, Cui J, et al. Survival benefit of resection surgery for pancreatic ductal adenocarcinoma with liver metastases: a propensity score-MAtched SEER database analysis. Cancers. 2021;14:57.CrossRefPubMedPubMedCentral Pausch TM, Liu X, Cui J, et al. Survival benefit of resection surgery for pancreatic ductal adenocarcinoma with liver metastases: a propensity score-MAtched SEER database analysis. Cancers. 2021;14:57.CrossRefPubMedPubMedCentral
29.
Zurück zum Zitat Tsai S, George B, Wittmann D, et al. Importance of normalization of CA19-9 levels following neoadjuvant therapy in patients with localized pancreatic cancer. Ann Surg. 2020;271:740–7.CrossRefPubMed Tsai S, George B, Wittmann D, et al. Importance of normalization of CA19-9 levels following neoadjuvant therapy in patients with localized pancreatic cancer. Ann Surg. 2020;271:740–7.CrossRefPubMed
30.
Zurück zum Zitat Reni M, Zanon S, Balzano G, et al. Selecting patients for resection after primary chemotherapy for non-metastatic pancreatic adenocarcinoma. Ann Oncol. 2017;28:2786–92.CrossRefPubMed Reni M, Zanon S, Balzano G, et al. Selecting patients for resection after primary chemotherapy for non-metastatic pancreatic adenocarcinoma. Ann Oncol. 2017;28:2786–92.CrossRefPubMed
31.
Zurück zum Zitat Maggino L, Malleo G, Marchegiani G, et al. Outcomes of primary chemotherapy for borderline resectable and locally advanced pancreatic ductal adenocarcinoma. JAMA Surg. 2019;154:932–42.CrossRefPubMedPubMedCentral Maggino L, Malleo G, Marchegiani G, et al. Outcomes of primary chemotherapy for borderline resectable and locally advanced pancreatic ductal adenocarcinoma. JAMA Surg. 2019;154:932–42.CrossRefPubMedPubMedCentral
32.
Zurück zum Zitat Kleive D, Sahakyan MA, Berstad AE, et al. Trends in indications, complications and outcomes for venous resection during pancreatoduodenectomy. Br J Surg. 2017;104:1558–67.CrossRefPubMed Kleive D, Sahakyan MA, Berstad AE, et al. Trends in indications, complications and outcomes for venous resection during pancreatoduodenectomy. Br J Surg. 2017;104:1558–67.CrossRefPubMed
33.
Zurück zum Zitat Belfiori G, Fiorentini G, Tamburrino D, et al. Vascular resection during pancreatectomy for pancreatic head cancer: a technical issue or a prognostic sign? Surgery. 2021;169:403–10.CrossRefPubMed Belfiori G, Fiorentini G, Tamburrino D, et al. Vascular resection during pancreatectomy for pancreatic head cancer: a technical issue or a prognostic sign? Surgery. 2021;169:403–10.CrossRefPubMed
34.
Zurück zum Zitat Nakagawa K, Sho M, Akahori T, et al. Significance of the inflammation-based prognostic score in recurrent pancreatic cancer. Pancreatology. 2019;19:722–8.CrossRefPubMed Nakagawa K, Sho M, Akahori T, et al. Significance of the inflammation-based prognostic score in recurrent pancreatic cancer. Pancreatology. 2019;19:722–8.CrossRefPubMed
35.
Zurück zum Zitat Ahmad J, Grimes N, Farid S, Morris-Stiff G. Inflammatory response related scoring systems in assessing the prognosis of patients with pancreatic ductal adenocarcinoma: a systematic review. Hepatobiliary Pancreat Dis Int. 2014;13:474–81.CrossRefPubMed Ahmad J, Grimes N, Farid S, Morris-Stiff G. Inflammatory response related scoring systems in assessing the prognosis of patients with pancreatic ductal adenocarcinoma: a systematic review. Hepatobiliary Pancreat Dis Int. 2014;13:474–81.CrossRefPubMed
36.
Zurück zum Zitat Perlmutter BC, Ali J, Turgut BC, et al. Correlation between physical status measures and frailty score in patients undergoing pancreatic resection. Surgery. 2022;171:711–7.CrossRefPubMed Perlmutter BC, Ali J, Turgut BC, et al. Correlation between physical status measures and frailty score in patients undergoing pancreatic resection. Surgery. 2022;171:711–7.CrossRefPubMed
Metadaten
Titel
Prognostic Factors After Pancreatectomy for Pancreatic Cancer Initially Metastatic to the Liver
verfasst von
Isabella Frigerio, MD, PhD
Giuseppe Malleo, MD, PhD
Matteo de Pastena, MD, PhD
Giacomo Deiro, MD
Niccolò Surci, MD
Filippo Scopelliti, MD
Alessandro Esposito, MD
Paolo Regi, MD
Alessandro Giardino, MD, PhD
Valentina Allegrini, MD
Claudio Bassi, MD
Roberto Girelli, MD
Roberto Salvia, MD, PhD
Giovanni Butturini, MD, PhD
Publikationsdatum
17.08.2022
Verlag
Springer International Publishing
Erschienen in
Annals of Surgical Oncology / Ausgabe 13/2022
Print ISSN: 1068-9265
Elektronische ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-022-12385-4

Weitere Artikel der Ausgabe 13/2022

Annals of Surgical Oncology 13/2022 Zur Ausgabe

Wie erfolgreich ist eine Re-Ablation nach Rezidiv?

23.04.2024 Ablationstherapie Nachrichten

Nach der Katheterablation von Vorhofflimmern kommt es bei etwa einem Drittel der Patienten zu Rezidiven, meist binnen eines Jahres. Wie sich spätere Rückfälle auf die Erfolgschancen einer erneuten Ablation auswirken, haben Schweizer Kardiologen erforscht.

Hinter dieser Appendizitis steckte ein Erreger

23.04.2024 Appendizitis Nachrichten

Schmerzen im Unterbauch, aber sonst nicht viel, was auf eine Appendizitis hindeutete: Ein junger Mann hatte Glück, dass trotzdem eine Laparoskopie mit Appendektomie durchgeführt und der Wurmfortsatz histologisch untersucht wurde.

Mehr Schaden als Nutzen durch präoperatives Aussetzen von GLP-1-Agonisten?

23.04.2024 Operationsvorbereitung Nachrichten

Derzeit wird empfohlen, eine Therapie mit GLP-1-Rezeptoragonisten präoperativ zu unterbrechen. Eine neue Studie nährt jedoch Zweifel an der Notwendigkeit der Maßnahme.

Ureterstriktur: Innovative OP-Technik bewährt sich

19.04.2024 EAU 2024 Kongressbericht

Die Ureterstriktur ist eine relativ seltene Komplikation, trotzdem bedarf sie einer differenzierten Versorgung. In komplexen Fällen wird dies durch die roboterassistierte OP-Technik gewährleistet. Erste Resultate ermutigen.

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

Karpaltunnelsyndrom BDC Leitlinien Webinare
CME: 2 Punkte

Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

Radiusfraktur BDC Leitlinien Webinare
CME: 2 Punkte

Das Webinar beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

Appendizitis BDC Leitlinien Webinare
CME: 2 Punkte

Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.